State of the ACTG
June, 2016

Daniel R. Kuritzkes, MD
Principal Investigator and Chair
AIDS Clinical Trials Group
Progress on ACTG Trials

- 10 studies opened to accrual
  - ACTG A5300 (PHOENIx feasibility study)
  - ACTG A5324 (InMIND)
  - ACTG A5329 (IFN-free treatment of HCV)
  - ACTG A5337 (Sirolimus)
  - ACTG A5338 (PK of rifampicin with DMPA and EFV)
  - ACTG A5340 (ATI after VRC01)
  - ACTG A5346 (Sitagliptin)
  - ACTG A5348 (LDV/SOF for HCV Retreatment)
  - ACTG A5350 (Effect of Visibiome on inflammation)
  - ACTG A5353 (DTG + 3TC dual therapy)
Progress on ACTG Trials

- 11 studies completed accrual
  - ACTG A5264 (Treatment of early KS)
  - ACTG A5288 (MULTI-OCTAVE [3rd-line ART in RLS])
  - ACTG A5290 (Rifabutin and LPV/r)
  - ACTG A5297 (PIs and malaria)
  - ACTG A5300 (PHOENIx feasibility study)
  - ACTG A5307 (Essentiality of INH)
  - ACTG A5316 (PK of ART and vaginal ring contraceptive)
  - ACTG A5317 (Methotrexate)
  - ACTG A5325 (Isotretinoin)
  - ACTG A5340 (ATI after VRC01)
  - ACTG A5342 (VRC01 and the reservoir)
Progress on ACTG Trials

- 9 studies completed follow-up
  - ACTG A5274 (REMEMBER)
  - ACTG A5297 (PIs and malaria)
  - ACTG A5298 (HPV vaccine)
  - ACTG A5305 (HPTN 069; MVC for PrEP)
  - ACTG A5307 (Essentiality of INH)
  - ACTG A5314 (Telmisartan)
  - ACTG A5317 (Methotrexate)
  - ACTG A5326 (anti-PD-L1 Ab)
  - ACTG A5340 (ATI after VRC01)
ACTG Accrual (June, 2015– May, 2016)

- 2116 enrolled into interventional trials
- 1326 enrolled into A5300 (over 6 months!)
  - 445 enrolled into other observational studies
  - 926 enrolled into A5128 or A5243

4813 participants enrolled across all studies

- 2544 participants enrolled at international sites
- 2108 participants enrolled at US sites
- 161 participants enrolled at non-ACTG CRSs
ACTG Abstracts and Publications

- 51 abstracts presented at 11 meetings
- 61 manuscripts published or in press
  - AIDS Res Hum Retrovir 3
  - AIDS 9
  - Ann Intern Med 2
  - Clin Infect Dis 10
  - JAIDS 8
  - J Infect Dis 6
  - Lancet 1
  - Nat Med 1